Summary: Liquidia Corp (NASDAQ:LQDA) saw insider activity earlier this month when Chief Financial Officer and Chief Operating Officer Michael Kaseta sold a total of 42,779 common shares across two trades executed on April 10 and April 13, 2026, for about $1.68 million. The sales, completed via pre-arranged Rule 10b5-1 plans, were transacted at prices spanning $38.37 to $40.1431. Kaseta also exercised incentive stock options and performance stock units to obtain 36,700 shares at exercise prices between $0.00 and $2.79, with the aggregate exercise cost reported as $66,460.
Details of the trades:
- On April 10, Kaseta sold 23,821 shares at a weighted-average price of $40.1431.
- On April 13, he sold 18,958 shares at $38.37 per share.
- The combined sale volume was 42,779 shares, bringing gross proceeds of approximately $1.68 million.
- Concurrently, Kaseta exercised 36,700 shares through incentive and performance-based awards at prices from $0.00 to $2.79, totaling $66,460 in exercise payments.
Share performance and recent financials: Liquidia shares are trading at $38.71, reflecting a 181% return over the past year and a 71% gain in the last six months. The company reported fourth-quarter 2025 revenue of $90.1 million, a 74% increase from the prior quarter, a performance attributed to the launch of its Yutrepia product. Despite revenue beating expectations, earnings per share for the quarter missed projections. Management has issued guidance targeting revenue in excess of $1 billion for 2027.
Analyst coverage and valuation commentary: Several brokerages adjusted their price targets following recent results and launch metrics. H.C. Wainwright raised its target to $55 while maintaining a Buy rating. BTIG increased its target to $50 with a Buy. BofA Securities reiterated a Buy rating and set a $44 target, citing Liquidia's position in the prostacyclin treatment market. Raymond James kept a Strong Buy rating with a $47 target and noted that Yutrepia's launch performance is comparable to that of another inhaled therapy. In addition, analysis from an investment-research product cited in company commentary flagged the stock as undervalued at current levels and noted analyst expectations for the company to reach profitability this year.
Context on the insider activity: The two sell transactions were carried out pursuant to Rule 10b5-1 trading plans, which allow insiders to execute pre-specified trades. The combination of option exercises and subsequent sales means Kaseta both increased his holdings by exercising awards and realized cash proceeds from share disposals.
Key points
- Insider transactions: Kaseta sold 42,779 shares for about $1.68 million and exercised 36,700 options at a cost of $66,460.
- Corporate fundamentals: Q4 2025 revenue of $90.1 million represented 74% quarter-over-quarter growth, driven by Yutrepia; EPS, however, missed estimates.
- Analyst outlook: Multiple firms increased price targets and maintain Buy or Strong Buy ratings, and at least one research analysis described the stock as undervalued with expected profitability this year.
Risks and uncertainties
- Earnings uncertainty - Despite top-line strength, the company missed on EPS in Q4 2025, indicating ongoing profitability risks in the near term.
- Execution risk on launch and growth - Continued revenue ramp depends on sustained performance of the Yutrepia launch and commercial execution.
- Insider trading interpretation - Insider sales executed under 10b5-1 plans can be driven by plan design rather than new information, which may create ambiguity for market observers.
Note: The article reflects reported transactions, company financials and analyst positions as provided, without additional interpretation beyond the disclosed items.